Engineered immune cells aim to clear leukemia before transplant

NCT ID NCT06197672

Recruiting now Disease control Sponsor: Huda Salman Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of CAR T-cell therapy, called CD4CAR, in people with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy targets a protein called CD4 on leukemia cells. The goal is to safely eliminate as much leukemia as possible so that patients can then receive a stem cell transplant, which may offer a chance for long-term control. The study will enroll 30 participants and focus on finding the safest and most effective dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD4CAR (a type of CAR T-cell therapy that targets CD4 on leukemia cells)
What this could lead to: If successful, this could provide a way to eliminate hard-to-treat AML and allow more patients to receive a potentially curative stem cell transplant.
What could go wrong: This is a very early phase 1 trial with only 30 participants, so safety and dosing are still being figured out. CAR T-cell therapy can cause severe side effects like cytokine release syndrome, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Riley Hospital for Children
RECRUITING

Indianapolis, Indiana, 46202, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Miami Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.